Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.

Demma MJ, Mapelli C, Sun A, Bodea S, Ruprecht B, Javaid S, Wiswell D, Muise E, Chen S, Zelina J, Orvieto F, Santoprete A, Altezza S, Tucci F, Escandon E, Hall B, Ray K, Walji A, O'Neil J.

Mol Cell Biol. 2019 Oct 28;39(22). pii: e00248-19. doi: 10.1128/MCB.00248-19. Print 2019 Nov 15.

2.

Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation.

Tabrizi M, Neupane D, Elie SE, Shankaran H, Juan V, Zhang S, Hseih S, Fayadat-Dilman L, Zhang D, Song Y, Ganti V, Judo M, Spellman D, Seghezzi W, Escandon E.

AAPS J. 2019 Mar 13;21(3):39. doi: 10.1208/s12248-019-0304-3.

PMID:
30868312
3.

The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.

Brunn ND, Mauze S, Gu D, Wiswell D, Ueda R, Hodges D, Beebe AM, Zhang S, Escandón E.

J Pharmacol Exp Ther. 2016 Mar;356(3):574-86. doi: 10.1124/jpet.115.229864. Epub 2015 Dec 15.

PMID:
26669426
4.

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.

Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, Barfield M, Xiao G, Escandon E, Wang W, Rock DA, Chemuturi NV, Moore DJ.

Drug Metab Dispos. 2016 May;44(5):617-23. doi: 10.1124/dmd.115.068049. Epub 2015 Dec 15. Review.

PMID:
26669328
5.

Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.

Alvarez HM, So OY, Hsieh S, Shinsky-Bjorde N, Ma H, Song Y, Pang Y, Marian M, Escandón E.

Drug Metab Dispos. 2012 Feb;40(2):360-73. doi: 10.1124/dmd.111.042531. Epub 2011 Nov 14.

PMID:
22083830
6.

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babé L, Senter PD, Fox JA, Schellenberger V.

Bioconjug Chem. 2006 Mar-Apr;17(2):410-8.

PMID:
16536473
7.
8.

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.

Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E.

Oncogene. 2002 May 16;21(22):3611-9.

9.

Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy.

Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Escandon E.

J Neuropathol Exp Neurol. 2001 Mar;60(3):263-73.

PMID:
11245210
10.

Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys.

Nguyen CB, Harris L, Szönyi E, Baughman SA, Hale VG, Dybdal NO, Sadick MD, Escandón E.

Drug Metab Dispos. 2000 May;28(5):598-607.

PMID:
10772641
11.

Stability and interactions of recombinant human nerve growth factor in different biological matrices: in vitro and in vivo studies.

Nguyen CB, Szönyi E, Sadick MD, Hotaling TE, Mendoza-Ramirez JL, Escandón E.

Drug Metab Dispos. 2000 May;28(5):590-7.

PMID:
10772640
12.

Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.

Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB.

J Pharmacol Exp Ther. 1999 Jan;288(1):371-8.

PMID:
9862791
13.
14.

The binding epitopes of neurotrophin-3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin.

Urfer R, Tsoulfas P, Soppet D, Escandón E, Parada LF, Presta LG.

EMBO J. 1994 Dec 15;13(24):5896-909.

15.

Regulation of neurotrophin receptor expression during embryonic and postnatal development.

Escandón E, Soppet D, Rosenthal A, Mendoza-Ramírez JL, Szönyi E, Burton LE, Henderson CE, Parada LF, Nikolics K.

J Neurosci. 1994 Apr;14(4):2054-68.

16.

Regulation of neurotrophin receptors during the maturation of the mammalian visual system.

Allendoerfer KL, Cabelli RJ, Escandón E, Kaplan DR, Nikolics K, Shatz CJ.

J Neurosci. 1994 Mar;14(3 Pt 2):1795-811.

17.

The rat trkC locus encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC12 cells.

Tsoulfas P, Soppet D, Escandon E, Tessarollo L, Mendoza-Ramirez JL, Rosenthal A, Nikolics K, Parada LF.

Neuron. 1993 May;10(5):975-90.

PMID:
8494648
18.

Characterization of neurotrophin receptors by affinity crosslinking.

Escandón E, Burton LE, Szönyi E, Nikolics K.

J Neurosci Res. 1993 Apr 15;34(6):601-13.

PMID:
8315660
19.

Neurotrophin gene expression by cell lines derived from human gliomas.

Hamel W, Westphal M, Szönyi E, Escandón E, Nikolics K.

J Neurosci Res. 1993 Feb 1;34(2):147-57.

PMID:
8450561
20.

The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor.

Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J, Burton LE, Stanton BR, Kaplan DR, Hunter T, Nikolics K, Parada LF.

Cell. 1991 May 31;65(5):895-903.

PMID:
1645620
21.
22.

Developmental expression of the chicken nerve growth factor receptor gene during brain morphogenesis.

Escandon E, Chao MV.

Brain Res Dev Brain Res. 1989 Jun 1;47(2):187-96.

PMID:
2545373
23.

[Larva migrans: therapeutic trials with thiabendazole].

De Escandon EM.

Int J Dermatol. 1971 Jul-Sep;10(3):192-7. Spanish. No abstract available.

PMID:
5116173

Supplemental Content

Loading ...
Support Center